- Poster presentation
- Open Access
Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study
© Gatell et al; licensee BioMed Central Ltd. 2010
Published: 8 November 2010
Once-daily fixed-dose combinations ABC/3TC and TDF/FTC are the preferred backbones in Europe . Long-term (>2 years) efficacy and safety of these compounds in simplification strategies are unknown.
333 HIV-1-infected adults on 3TC-containing triple regimens with <200 copies/mL for at least 6 months had their NRTI backbone randomly switched to either ABC/3TC or TDF/FTC. Pre-planned results at 1 year have been already published . Treatment failure (defined as virological failure, discontinuation of study therapy, withdrawal of consent, lost to follow-up, progression to AIDS, or death), virological failure (defined as confirmed plasma HIV-1 RNA >200 copies/mL), adverse events, and changes in CD4 cells, fasting plasma lipids, glomerular filtration rate (GFR) (Cockcroft-Gault), and transaminases at 3 years were compared between arms.
Treatment failure increased from 32 (19%) to 58 (35%) patients on ABC/3TC and from 22 (13%) to 61 (37%) patients on TDF/FTC at 1 and 3 years, respectively (HR for ABC/3TC treatment failure at 3 years 0.99, 95% CI 0.69-1.41). The most common reasons for treatment failure at 3 years in both arms were lost to follow-up/withdrawal of consent (68 patients, 20%) or discontinuation of study drugs for reasons other than adverse events (15 patients, 5%). Total discontinuations due to adverse events increased from 17 at 1-year to 18 patients at 3-years on ABC/3TC and from 9 at 1-year to 10 patients at 3-years on TDF/FTC. Total virological failures increased from 4 at 1-year to 6 patients at 3-years on ABC/3TC while no patient on TDF/FTC developed virological failure at 1-year and through 3-years (HR for ABC/3TC virological failure at 3 years 3.59, 95% CI 0.77-6.42). Change from baseline (mg/dL) in triglycerides (+1 vs -29, P=0.008), total cholesterol (+12 vs -12, P<0.001), LDL-cholesterol (+1 vs -1, P<0.001), and HDL-cholesterol (+3 vs -2, P<0.001) were increased in patients on ABC/3TC compared with decreases in patients on TDF/FTC, although total-to-HDL cholesterol ratio remained almost identical in both arms. There were no significant changes in GFR or transaminases in each arm at 3-years.
From the 1-year analysis, we observed two additional virological failures in patients on ABC/3TC; there were no virological failures in patients on TDF/FTC over 3 years. Through 3 years long-term safety/tolerability was very good. Differential lipid effects between arms were maintained at 3 years.
- European AIDS Clinical Society: Guidelines on the clinical management and treatment of HIV-infected adults in Europe. [http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf]
- Martínez E, Arranz JA, Podzamczer D, et al: A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose aba-cavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. JAIDS. 2009, 51: 290-297.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.